Key result
Novel biomarkers fail to distinguish CVD in CKD, while diabetes is linked to ~8-fold risk.
Why the study?
Cardiovascular disease is a major cause of morbidity and mortality in chronic kidney disease patients, and the roles of CVD biomarkers in this population need evaluation.
Do serum levels of hs-CRP, CysC, ADMA, and SDMA differ between stage 2-4 CKD patients with and without cardiovascular disease?
Case-Control (n=62)
No
Do serum levels of hs-CRP, CysC, ADMA, and SDMA differ between stage 2-4 CKD patients with and without cardiovascular disease?
Traditional risk factors such as age, diabetes mellitus, hypertension, and renal function remain the most important predictors of cardiovascular disease in CKD patients, rather than novel biomarkers like hs-CRP, CysC, ADMA, and SDMA.
Answers are grounded in this paper and cite their sources.
Biomarker levels did not differ by CVD status in stage 2-4 CKD; leaves open their added prognostic value beyond traditional risks.
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients.This study aimed to determine the roles of CVD biomarkers in CKD patients.This was a case-control study which recruited consecutive patients with stage 2-4 CKD patients with and without CVD.Serum levels of highly-sensitive C reactive protein (hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were measured.Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited.Twenty three (37.1%) of them had CVD.Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05).Diabetic patients had 8 times (95% CI 1.25-51.77,p< 0.05) higher risk to develop CVD.CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m 2 p<0.05) and a lower triglyceride levels (1.3 (1.1-1.7)vs 1.8 (1.4-2.3)mmol/L, p<0.05), compared to those without CVD.Fasting blood sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05).There were no differences in their mean serum levels of hs-CRP, CysC, ADMA and SDMA.Risk factors including age, diabetes mellitus, hypertension and renal functions were still the most important CVD risk factors in CKD patients.
No takes yet. Share an insight, caveat, or question.
Gafor et al. (2018) conducted a case-control in Stage 2-4 Chronic Kidney Disease (n=62). Diabetes mellitus vs. Non-diabetic patients was evaluated on Cardiovascular disease (CVD) (OR 8.04, 95% CI 1.25-51.77, p=0.028). In patients with stage 2-4 chronic kidney disease, novel biomarkers (hs-CRP, CysC, ADMA, SDMA) did not differ significantly between those with and without cardiovascular disease, whereas diabetes mellitus was associated with an 8-fold higher risk of CVD (OR 8.04).
Synapse has enriched 10 related papers. Consider them for comparative context: